# Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes

Study · id `cardio:ct-nct05834868` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05834868](<https://clinicaltrials.gov/study/NCT05834868>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05834868

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1040 participants.

## Technical summary

Registry record NCT05834868. Randomized; no masking; primary purpose treatment. Start 2022-05-06 (actual); primary completion 2024-12-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1040 participants (enrolled count; ClinicalTrials.gov record NCT05834868, source copy `cardio:ctgov-nct05834868-2025-12-22`, retrieved 2026-10-26)
- Started: 2022-05-06 (actual) (ClinicalTrials.gov record NCT05834868, source copy `cardio:ctgov-nct05834868-2025-12-22`, retrieved 2026-10-26)
- Primary completion: 2024-12-10 (actual) (ClinicalTrials.gov record NCT05834868, source copy `cardio:ctgov-nct05834868-2025-12-22`, retrieved 2026-10-26)
- Completion: 2024-12-31 (actual) (ClinicalTrials.gov record NCT05834868, source copy `cardio:ctgov-nct05834868-2025-12-22`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05834868, source copy `cardio:ctgov-nct05834868-2025-12-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05834868-2025-12-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): THDB0206 Injection
- Intervention (Drug): Insulin Lispro Injection
- Lead sponsor: Tonghua Dongbao Pharmaceutical Co.,Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 70bfb55d57e3daf88b7665a676906b1e6bd4c887f9b90df240eb4292ef8a3a59
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
